Highlighted PresentationsStructural heart disease

SOLACI-SBHCI 2023 | Alternative Vascular Access for Structural Heart Interventions – Dr. Diego Silveira da Costa

solaci
solaci
459
0

Read the most outstanding articles from SOLACI-SBHCI 2023 Congress.

In this case, check the presentation by Dr. Diego Silveira da Costa, entitled “Alternative Vascular Access for Structural Heart Interventions”

Diego-Silveira-da-Costa-solaci-sbhci-2023

Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Previous article
Long Term Outcomes after Complex PCI According to Operator Experience and Use of IVUS
Next article
SOLACI-SBHCI 2023 | Mitral Valve Interventions beyond the TEER Era: Time to Re-Evaluate Innovation Priorities?- Dr. Eberhard Grube
solaci
solaci

More articles by this author

One-Year Results of ENCIRCLE: Percutaneous Mitral Valve Replacement in Patients Ineligible for Surgery or TEER

Dr. Omar Tupayachi - 0
Symptomatic mitral regurgitation (MR) in patients who are not candidates for surgery or transcatheter edge-to-edge repair (TEER) remains a highly complex clinical scenario associated...

Can Coronary CT Angiography Replace Invasive Coronary Angiography in Pre-TAVI Coronary Assessment?

Dr. Juan Manuel Pérez - 0
Coronary artery disease coexists in approximately half of patients undergoing transcatheter aortic valve implantation, making coronary assessment prior to the procedure essential. Invasive coronary...

Valve-in-Valve in Small Surgical Aortic Bioprostheses: Balloon-Expandable or Self-Expanding? Three-Year Results from the LYTEN Trial

Dr. Juan Manuel Pérez - 0
Dysfunction of small surgical aortic bioprostheses represents a challenging scenario for transcatheter aortic valve replacement in the valve-in-valve setting, due to the higher incidence...

Can TAVI Be Safely Performed in Patients With Bicuspid Aortic Valve?

Dr. Juan Manuel Pérez - 0
Bicuspid aortic valve (BAV) represents an anatomical challenge for transcatheter aortic valve replacement (TAVR) due to the frequent presence of elliptical annuli, fibroc calcific...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

Mitral valve

One-Year Results of ENCIRCLE: Percutaneous Mitral Valve Replacement in Patients Ineligible for Surgery or TEER

Symptomatic mitral regurgitation (MR) in patients who are not candidates for surgery or transcatheter edge-to-edge repair (TEER) remains a highly...
Dr. Omar Tupayachi -
SOLACI Sessionsspot_img

Recent Articles

CRT 2026 | CUT-DRESS Trial: Lesion Preparation with Cutting Balloon

Dr. Omar Tupayachi - 0
In-stent restenosis (ISR) continues to represent a relevant clinical challenge in contemporary coronary angioplasty practice. Despite advances in drug-eluting stents, neointimal hyperplasia and suboptimal...

CRT 2026 | Clopidogrel vs Aspirin as Long-Term Monotherapy After Coronary Angioplasty

Dr. Omar Tupayachi - 0
The use of aspirin as chronic antiplatelet therapy after percutaneous coronary intervention (PCI) has historically been the standard recommended by international guidelines. However, recent...

Bioresorbable devices vs DES in patients at high risk of restenosis. Seven-year follow-up of the COMPARE-ABSORB trial

Dr. Andrés Rodríguez - 0
Studies with second-generation drug-eluting stents (DES) have shown that the rate of target lesion failure (TLF) increases linearly up to 5–10 years of follow-up,...